Cardiac Ablation Systems Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Radiofrequency (RF) Ablation, Electrical Ablation, Cryoablation, Ultrasound Ablation, and Microwave Ablation), By Application (Cardiac Rhythm Management, Open Surgery, and Others), By End-User (Hospitals, Cardiac Centres, and Ambulatory Surgical Centers), and Region

Cardiac Ablation Systems Market was valued at US$ 957.3 million in 2022 and is expected to grow at a significant CAGR of 12.7% from 2024-2030. The increased demand for improved minimally invasive procedures, particularly in developed countries, is attributed to the market's rise. Several advantages associated with minimally invasive procedures, such as reduced surgical complications, faster recovery, shorter hospital stays, and effective post-surgical pain management, are expected to drive patient preference for such treatments in the coming years, positively impacting market expansion. The advancement of the market would be aided by increasing public knowledge of the latest treatment options available for heart disorders. The government is introducing several programs to raise awareness and improve cardiac disease management.

Furthermore, coordinated efforts by the government and non-government groups to provide patients with cost-effective care will have an impact on procedural volume. The need for products will rise in the coming years as the number of ablation treatments rises. The high risk associated with cardiac ablation operations, as well as the current regulatory environment, are impeding the growth of the cardiac ablation system market. There will be a growing need for cardiac ablation devices as the prevalence of cardiovascular illnesses rises. The entire cardiac ablation devices system market is also influenced positively by advantageous reimbursement rules, the presence of several significant players, promising long-term survival, and a multimodal approach. Other reasons, such as decreasing radiofrequency ablation costs and ease of use, will also contribute to the global expansion of the cardiac ablation device system market.

The radiofrequency ablators segment has the most significant market share based on product. The cardiac ablation market's radiofrequency (RF) ablators sector is expected to rise faster CAGR through 2028, owing to increased product availability. Several advantages of radiofrequency (RF) ablation, such as cost-effectiveness and rapid alleviation, are expected to drive segment expansion in the next years. Furthermore, RF ablation improves mobility, reduces the need for medicines, and provides long-term pain relief.

Key Developments

• In Jan 2022, Medtronic plc a global leader in healthcare technology, entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF). The acquisition expands the Medtronic portfolio of advanced cardiac ablation products and accessories to meet physician needs within a growing patient population.
• In Oct 202, Boston Scientific Corporation entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition will expand the Boston Scientific electrophysiology and structural heart product portfolios to include the radiofrequency (RF) NRG® and VersaCross® Transseptal Platforms as well as a family of guidewires, sheaths, and dilators used to support left heart access.